Acclarent, a Johnson & Johnson (J&J) unit, has agreed to pay $18 million to resolve allegations that it marketed a sinus spacer product as a drug delivery device without obtaining an FDA sign off for that use. As a result, health care providers submitted false claims to Medicare and other federal programs, the U.S. Department of Justice (DOJ) alleged.